Neural cell adhesion molecule (NCAM/CD56) expression in acute myeloid leukemia (AML) has been associated with extramedullary leukemia, multidrug resistance, shorter remission and survival. Recently, Bloomfield et al. published a succinct review of issues surrounding the AML prognostication and current therapeutics. However, we want to reiterate the prognostic value and therapeutic potential of CD56 that is frequently expressed in AML as was also reported by their own group earlier. In addition, novel RUNX1 isoforms contribute in controlling CD56 expression in AML cells. Anti-CD56 antibody therapy deserves exploration as an arsenal against AML patients expressing CD56. Relevantly, targeting RNA splicing machinery or RUNX1 isoform-specific siRNA may also become part of future therapeutic strategies for AML with CD56 overexpression.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.hemonc.2015.11.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enhanced osteogenic potential of iPSC-derived mesenchymal progenitor cells following genome editing of GWAS variants in the RUNX1 gene.
Bone Res
December 2024
Department of Orthopaedics, Emory University School of Medicine, Atlanta, GA, USA.
Recent genome-wide association studies (GWAS) identified 518 significant loci associated with bone mineral density (BMD), including variants at the RUNX1 locus (rs13046645, rs2834676, and rs2834694). However, their regulatory impact on RUNX1 expression and bone formation remained unclear. This study utilized human induced pluripotent stem cells (iPSCs) differentiated into osteoblasts to investigate these variants' regulatory roles.
View Article and Find Full Text PDFCebpa is required for haematopoietic stem and progenitor cell generation and maintenance in zebrafish.
Open Biol
November 2024
The Innovation Centre of Ministry of Education for Development and Diseases, School of Medicine, South China University of Technology, Guangzhou, Guangdong 510006, People's Republic of China.
The CCAAT enhancer binding protein alpha (CEBPA) is crucial for myeloid differentiation and the balance of haematopoietic stem and progenitor cell (HSPC) quiescence and self-renewal, and its dysfunction can drive leukemogenesis. However, its role in HSPC generation has not been fully elucidated. Here, we utilized various zebrafish mutants to investigate the function of Cebpa in the HSPC compartment.
View Article and Find Full Text PDFTranscriptional regulatory program controlled by MYB in T-cell acute lymphoblastic leukemia.
Leukemia
December 2024
Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
The transcription factor MYB is frequently upregulated in T-cell acute lymphoblastic leukemia (T-ALL), a hematological malignancy originating from T-cell precursors. Here, we demonstrate that MYB plays a crucial role by regulating genes essential for T-ALL pathogenesis. Integrative analysis reveals a long MYB isoform, ENST00000367814.
View Article and Find Full Text PDFRUNX1 isoforms regulate RUNX1 and target genes differentially in platelets-megakaryocytes: association with clinical cardiovascular events.
J Thromb Haemost
December 2024
Sol Sherry Thrombosis Research Center, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, USA; Department of Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, USA. Electronic address:
Article Synopsis
- The RUNX1 gene produces two isoforms (RUNX1B and RUNX1C) that play roles in regulating each other and their target genes in blood cells like megakaryocytes and platelets.
- Studies were conducted in various cell types and platelets from healthy individuals to understand the influence of these isoforms on gene regulation and their association with cardiovascular disease (CVD) events.
- The findings suggest that RUNX1 isoforms autoregulate themselves and differentially control target genes, indicating their potential roles in acute cardiovascular events.
Mutational cooperativity of RUNX1::RUNX1T1 isoform 9a and oncogenic NRAS in zebrafish myeloid leukaemia.
Biol Open
September 2024
Leukaemia and Blood Cancer Research Unit, Department of Molecular Medicine and Pathology, University of Auckland, Auckland 1023, New Zealand.
RUNX1::RUNX1T1 (R::RT1) acute myeloid leukaemia (AML) remains a clinical challenge, and further research is required to model and understand leukaemogenesis. Previous zebrafish R::RT1 models were hampered by embryonic lethality and low penetrance of the malignant phenotype. Here, we overcome this by developing an adult zebrafish model in which the human R::RT1 isoform 9a is co-expressed with the frequently co-occurring oncogenic NRASG12D mutation in haematopoietic stem and progenitor cells (HSPCs), using the Runx1+23 enhancer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!